Sucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Recommendation of “Hold” by Analysts

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been given a consensus recommendation of “Hold” by the fourteen brokerages that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $20.56.

Several brokerages recently issued reports on SCMP. BidaskClub raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 12th. Leerink Swann reissued a “market perform” rating and issued a $15.00 price target on shares of Sucampo Pharmaceuticals in a report on Tuesday, January 2nd. Zacks Investment Research downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 9th. Nomura began coverage on Sucampo Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $43.00 price target on the stock. Finally, UBS downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price target on the stock. in a report on Friday, January 5th.

How to Become a New Pot Stock Millionaire

A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company increased its position in shares of Sucampo Pharmaceuticals by 4.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 790 shares during the period. Nationwide Fund Advisors increased its position in shares of Sucampo Pharmaceuticals by 135.2% during the 3rd quarter. Nationwide Fund Advisors now owns 32,008 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 18,400 shares during the period. Crossmark Global Holdings Inc. acquired a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at $153,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at $207,000. Finally, Bank of New York Mellon Corp increased its position in shares of Sucampo Pharmaceuticals by 13.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 414,304 shares of the biopharmaceutical company’s stock valued at $4,888,000 after purchasing an additional 47,639 shares during the period. 67.09% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:SCMP traded up $0.05 during trading hours on Thursday, reaching $18.05. 303,068 shares of the stock were exchanged, compared to its average volume of 2,557,332. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/04/17/sucampo-pharmaceuticals-inc-scmp-given-consensus-recommendation-of-hold-by-analysts.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply